Atomoxetine in the Treatment of Binge Eating Disorder

Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients

The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

Inclusion Criteria:

• Subjects will meet the DSM-IV criteria for a diagnosis of binge-eating disorder for at least the last 6 months
• In addition, subjects will report at least 3 binge eating episodes per week for the last 6 months prior to randomization

Exclusion Criteria:

• Have concurrent symptoms of bulimia nervosa or anorexia nervosa
• Women who are pregnant, lactating, or of child bearing potential who are not using adequate contraceptive measures
• Patients who are displaying clinically significant suicidality or homicidality